- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Updates, 30-09-2025: Press Release
30-09-2025 | 04:57 pm
30-09-2025 | 04:57 pm
Lupin has received U.S. FDA approval for Rivaroxaban for Oral Suspension, 1 mg/mL, a generic for Xarelto®. This targets an estimated USD 11 million (approx ₹91.3 Cr) annual market in the U.S., expanding Lupin's pediatric offerings.
No comments yet. Be the first to comment!